DURHAM, N.C., June 21 /PRNewswire/ -- A press release from AstraZeneca reported that the company is teaming up with Humana, Inc. to study how to improve patient compliance through the use of Voice Activated Technology (VAT). The study will focus on improving cholesterol-lowering drug compliance by examining factors such as motivation, self-confidence, and barriers to compliance.
Cutting Edge Information’s report, “Pharmaceutical Patient Compliance and Disease Management,” describes how patient noncompliance can bring about serious health and financial problems for both patients and pharmaceutical companies. Patients with chronic illnesses, such as diabetes and hypertension, pose serious threats to their health by not complying with drug regimens.
Those patients who do not comply with dosage and treatment regimens often must provide additional funding for further treatment, due to the health consequences caused by noncompliance. Estimates conclude that noncompliance causes approximately 125,000 deaths per year and is responsible for 10-20% of annual hospital and nursing home admissions, according to research conducted by Cutting Edge Information.
Noncompliance also causes the pharmaceutical industry to experience a heavy financial blow. Cutting Edge Information’s analysts found that pharmaceutical companies lose revenue and miss opportunities to form consumer- product loyalties and long-term relationships with patients when noncompliance occurs.
“Pharmaceutical Patient Compliance and Disease Management” shows how pharmaceutical companies develop customer-focused programs for patients and other consumers. The study contains business practices from top companies including Pfizer, Merck, Aventis, GlaxoSmithKline, Bristol-Myers Squibb, Novartis and Eli Lilly.
According to the report, key compliance challenges include the following “big-five” issues:
- The patient fails to fill initial prescription - The patient takes an incorrect dosage - The patient takes medication at the wrong time - The patient forgets to take one or more doses - The patient stops taking the medication too soon
For more information on Cutting Edge Information’s report, “Pharmaceutical Patient Compliance and Disease Management,” or to learn about other research being conducted by Cutting Edge Information, contact Eric Bolesh at 919-433-0209 or at eric_bolesh@cuttingedgeinfo.com.
Cutting Edge Information is your one-stop shop for pharmaceutical business research. Our reports will help your team build pharmaceutical marketing budgets and plans, optimize your alliances, and maximize lifetime customer value. Move ahead of your competition with information from the cutting edge.
Cutting Edge Information
CONTACT: Eric Bolesh of Cutting Edge Information, +1-919-433-0209, oreric_bolesh@cuttingedgeinfo.com
Web site: http://www.cuttingedgeinfo.com//
